SCHEMBL22232172

SCHEMBL22232172

CCN(C)C=Nc1cc(C)cc(Nc2ccc(OC)c(F)c2)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 4/20 0.39
BCL6 P41182 4/20 0.35
ABCG2 Q9UNQ0 2/20 0.34
ABCB1 P08183 1/20 0.34
ABCC1 P33527 1/20 0.34
THRB P10828 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GALR1 P47211 2/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
TUBB1 Q9H4B7 1/20 0.32
P2RX3 P56373 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MITF O75030 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
NCOR2 Q9Y618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22232170 1.00 GALR2 (0.39) GALR2BCL6ABCG2ABCB1ABCC1
SCHEMBL22231919 0.92 KCNH2 (0.40) GALR2BCL6THRBHPGDSMN1; SMN2
SCHEMBL22231921 0.92 KCNH2 (0.40) GALR2BCL6THRBHPGDSMN1; SMN2
SCHEMBL22232164 0.88 RAPGEF4 (0.40) HPGDRAPGEF4KDM4EIDO1TDO2
SCHEMBL22232167 0.88 RAPGEF4 (0.40) HPGDRAPGEF4KDM4EIDO1TDO2
SCHEMBL22231920 0.85 GALR2 (0.37) GALR2BCL6ABCG2ABCB1ABCC1
SCHEMBL22231917 0.85 GALR2 (0.37) GALR2BCL6ABCG2ABCB1ABCC1
SCHEMBL22232370 0.84 MAPT (0.36) THRBSMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL22232593 0.84 BPTF (0.33)
SCHEMBL22232592 0.84 BPTF (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP claimed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO claimed
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US disclosed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP disclosed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP disclosed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS GALR2 2951/4885BCL6 4167/4885ABCG2 219/4885
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof CBR1, CBR3, HCCS GALR2 679/4885BCL6 786/4885ABCG2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.